IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL; BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL;
BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
WARREN, N.J., Nov. 13 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU) today announced that the U.S. Patent and Trademark Office ruled, in a final appeal, to allow the issuance to Immunomedics of patent claims originally filed in 1985.
The patent claims cover the use of radioisotopes or magnetic resonance contrast agents attached to monoclonal antibodies or antibody fragments that bind selectively to normal body organs and tissues. These new reagents enable images to be made of normal organs of the body by nuclear medicine or magnetic resonance imaging devices, whereby disease areas show up as defects or "cold spots."
Dr. David M. Goldenberg, the inventor of this new technology, commented, "These claims have very broad and general application to improved radiological diagnosis. For example, a bone marrow-targeting antibody can be given to reveal cancer in this tissue, particularly metastasis, or spread, from cancers of the breast or prostate."
Russell C. McLauchlan, president of Immunomedics, said, "This new patent, which will bring the total issued to Immunomedics in the U.S. to 22 and 67 in foreign countries, provides a new class of imaging agents which should improve early and more accurate diagnosis of various diseases, including cancer and infections. We are already in clinical trials with a granulocyte imaging agent which may also permit the visualization of cancer spread to the bone marrow. "This should enable physicians to better stage the extent of cancer in patients," he added.
Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
/CONTACT: Amy Factor of Immunomedics, 908-647-5400/
(IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU: CK-OS -- NY016 -- 3838 11/13/91 10:12 EST